|
|
Volumn 6, Issue 2, 2009, Pages 94-95
|
|
Reflections on the regulation of the Polypill
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ACETYLSALICYLIC ACID PLUS PRAVASTATIN;
AMLODIPINE PLUS ATORVASTATIN;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
CARDIOVASCULAR AGENT;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
FOLIC ACID;
HYDROCHLOROTHIAZIDE;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
UNCLASSIFIED DRUG;
ARTICLE;
CARDIOVASCULAR DISEASE;
DRUG APPROVAL;
DRUG CHOICE;
DRUG DOSAGE FORM;
DRUG EFFICACY;
DRUG FORMULATION;
DRUG INDICATION;
DRUG LEGISLATION;
DYSLIPIDEMIA;
HUMAN;
HYPERTENSION;
LOW DRUG DOSE;
PHARMACODYNAMICS;
POLYPILL;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
RISK FACTOR;
ADRENERGIC BETA-ANTAGONISTS;
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
ASPIRIN;
CARDIOVASCULAR AGENTS;
CARDIOVASCULAR DISEASES;
DRUG APPROVAL;
DRUG COMBINATIONS;
EUROPE;
FOLIC ACID;
GOVERNMENT REGULATION;
HEALTH POLICY;
HUMANS;
HYDROCHLOROTHIAZIDE;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
PATIENT SELECTION;
PRACTICE GUIDELINES AS TOPIC;
RISK ASSESSMENT;
TREATMENT OUTCOME;
|
|
EID: 59549090274
PISSN: 17434297
EISSN: 17434300
Source Type: Journal
DOI: 10.1038/ncpcardio1416 Document Type: Article |
|
Times cited : (4)
|
|
References (6)
|
